Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2022-03-31 Regulatory Filings
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
FORM NT 10-K
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 filing, which is a notification of late filing for a Form 10-K annual report. It explicitly states that the registrant, JATT Acquisition Corp, is unable to file its Annual Report on Form 10-K for the year ended December 31, 2021, within the prescribed time period and requests an extension. The document does not contain the actual 10-K report or financial data but is a notification about the delay in filing the 10-K. According to the 'MENU VS MEAL' rule, such a notification is not the report itself but an announcement related to the report filing status. Therefore, the correct classification is Regulatory Filings (RNS), as it is a regulatory announcement about the late filing of a 10-K report, not the 10-K report itself.
2022-03-31 English
JATT 13G
Major Shareholding Notification
2022-02-08 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It details an amendment to Forward Purchase Agreements related to financing arrangements for a business combination. The content focuses on capital raising and financing terms, including issuance of shares and convertible notes. There are no financial statements or comprehensive financial performance data presented, nor is it an announcement of voting results, management changes, or legal proceedings. The document is not a full annual or quarterly report but rather an update on financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about financing agreements, supporting a high confidence level.
2022-02-02 English
SC 13G
Major Shareholding Notification
2022-01-21 English
FORM 10-Q
Interim / Quarterly Report Q3 2021
2021-11-19 English
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 filed with the SEC, which is a Notification of Late Filing for a Form 10-Q quarterly report. It explains the reason for the delay in filing the Form 10-Q for the quarterly period ended June 30, 2021. The document does not contain the actual financial statements or substantive financial data of the 10-Q report itself, but rather is a notification about the late filing of that report. According to the rules, such a notification is a Regulatory Filing (RNS) because it is a compliance document related to filing deadlines and does not constitute the actual quarterly report.
2021-11-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.